- Home
- IBRX vs CPK Comparison
IBRX vs CPK Comparison
Compare IBRX & CPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- CPK
- Stock Information
- Founded
- IBRX 2014
- CPK 1990
- Country
- IBRX United States
- CPK United States
- Employees
- IBRX N/A
- CPK N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- CPK Oil & Gas Production
- Sector
- IBRX Health Care
- CPK Utilities
- Exchange
- IBRX Nasdaq
- CPK Nasdaq
- Market Cap
- IBRX 2.3B
- CPK 2.8B
- IPO Year
- IBRX N/A
- CPK N/A
- Fundamental
- Price
- IBRX $2.44
- CPK $123.36
- Analyst Decision
- IBRX Strong Buy
- CPK Hold
- Analyst Count
- IBRX 5
- CPK 2
- Target Price
- IBRX $11.40
- CPK $124.50
- AVG Volume (30 Days)
- IBRX 7.6M
- CPK 118.7K
- Earning Date
- IBRX 08-05-2025
- CPK 08-07-2025
- Dividend Yield
- IBRX N/A
- CPK 2.22%
- EPS Growth
- IBRX N/A
- CPK 16.75
- EPS
- IBRX N/A
- CPK 5.60
- Revenue
- IBRX $56,600,000.00
- CPK $866,700,000.00
- Revenue This Year
- IBRX $567.98
- CPK $13.95
- Revenue Next Year
- IBRX $160.56
- CPK $3.52
- P/E Ratio
- IBRX N/A
- CPK $22.03
- Revenue Growth
- IBRX 4227.22
- CPK 18.91
- 52 Week Low
- IBRX $1.83
- CPK $111.00
- 52 Week High
- IBRX $7.48
- CPK $136.73
- Technical
- Relative Strength Index (RSI)
- IBRX 40.38
- CPK 58.10
- Support Level
- IBRX $2.33
- CPK $118.84
- Resistance Level
- IBRX $2.46
- CPK $120.85
- Average True Range (ATR)
- IBRX 0.15
- CPK 1.96
- MACD
- IBRX -0.03
- CPK 0.15
- Stochastic Oscillator
- IBRX 14.10
- CPK 76.74
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About CPK Chesapeake Utilities Corporation
Chesapeake Utilities Corp is a diversified energy delivery company that is engaged in natural gas transmission and distribution, electricity generation and distribution, propane gas distribution, mobile compressed natural gas utility services and solutions and other businesses. The company operates in two reportable segments, Regulated Energy and Unregulated Energy. The company's natural gas and electric distribution operations in Delaware, Maryland and Florida are subject to regulation by PSC. Eastern Shore, its natural gas transmission is subject to regulation by the FERC and Peninsula Pipeline and Aspire Energy Express, its intrastate pipeline subsidiaries, are subject to regulation by the Florida PSC and Public Utilities Commission of Ohio, respectively.